Table 3.
Risk factors of STEMI patients with COVID-19.
| Baseline characteristic | OR [95% CI] | Z (P value) | Heterogeneity of study design | ||
|---|---|---|---|---|---|
| χ2 | Df (P value) | I2 (%) | |||
| Age | −0.50 [−2.73, 1.73] | 0.44 (.66) | 11.41 | 4 (.02) | 64% |
| Gender (male) | 1.01 [0.74, 1.36] | 0.04 (.97) | 1.73 | 4 (.79) | 0% |
| Hypertension | 0.05 [−0.06, 0.15] | 0.91 (.36) | 10.65 | 4 (.03) | 62% |
| Diabetes mellitus | 1.26 [0.96, 1.65] | 1.69 (.09) | 7.63 | 4 (.11) | 48% |
| Hyperlipidemia | 1.33 [0.74, 2.40] | 0.95 (.34) | 19.32 | 4 (.0007) | 79% |
| Smoking | 0.86 [0.64, 1.16] | 0.99 (.32) | 4.42 | 4 (.35) | 10% |
| Previous MI | 1.13 [0.53, 2.38] | 0.32 (.75) | 12.99 | 4 (.01) | 69% |
| Door-to-balloon time | 6.31 [0.99, 11.63] | 2.32 (.02) | 9.04 | 4 (.06) | 56% |
| Total ischemia time | 5.44 [−109.32, 120.20] | 0.09 (.93) | 28.23 | 4 (.0001) | 86% |
| Gp2b3a inhibitor use | 2.71 [1.53, 4.81] | 3.41 (.0006) | 14.25 | 4 (.007) | 72% |
| Thrombus aspiration use | 1.84 [0.99, 3.44] | 1.91 (.06) | 9.39 | 4 (.05) | 57% |
| TIMI flow 3 at end of case | 0.48 [0.34, 0.67] | 4.32 (<.0001) | 3.91 | 4 (.42) | 0% |
| In-hospital mortality | 5.16 [3.53, 7.53] | 8.50 (<.00001) | 7.19 | 4 (.13) | 44% |
95% CI = 95% confidence interval, COVID-19 = coronavirus disease 2019, GP2b3a = glycoprotein Iib/IIIa, MI = myocardial infarction, ORs = odds ratios, STEMI = ST-segment elevation myocardial infarction, TIMI = thrombolysis in myocardial infarction.